COVID-19 impact on thrombotic complications in cancer patients

Aim: to study the features of thrombotic complications in cancer patients during COVID-19 infection, and identify the most significant diagnostic and prognostic criteria.Materials and Methods. Within the framework of cohort non-randomized study, there were analyzed the course of coronavirus infectio...

Full description

Saved in:
Bibliographic Details
Main Authors: A. V. Vorobev, S. E. Einullaeva, A. S. Borodulin, M. A. Shikina, S. A. Aliev, A. G. Solopova, V. N. Galkin, A. E. Ivanov, V. O. Bitsadze, J. Kh. Khizroeva, D. V. Blinov, J.-C. Gris, I. Elalamy, A. D. Makatsariya
Format: Article
Language:Russian
Published: IRBIS LLC 2024-07-01
Series:Акушерство, гинекология и репродукция
Subjects:
Online Access:https://www.gynecology.su/jour/article/view/2088
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849697350102024192
author A. V. Vorobev
S. E. Einullaeva
A. S. Borodulin
M. A. Shikina
S. A. Aliev
A. G. Solopova
V. N. Galkin
A. E. Ivanov
V. O. Bitsadze
J. Kh. Khizroeva
D. V. Blinov
J.-C. Gris
I. Elalamy
A. D. Makatsariya
author_facet A. V. Vorobev
S. E. Einullaeva
A. S. Borodulin
M. A. Shikina
S. A. Aliev
A. G. Solopova
V. N. Galkin
A. E. Ivanov
V. O. Bitsadze
J. Kh. Khizroeva
D. V. Blinov
J.-C. Gris
I. Elalamy
A. D. Makatsariya
author_sort A. V. Vorobev
collection DOAJ
description Aim: to study the features of thrombotic complications in cancer patients during COVID-19 infection, and identify the most significant diagnostic and prognostic criteria.Materials and Methods. Within the framework of cohort non-randomized study, there were analyzed the course of coronavirus infection in 72 hospitalized patients with uterine cancer (n = 22), cervical cancer (n = 19), ovarian cancer (n = 24) as well as vaginal and vulvar cancer (n = 7). All patients hospitalized for COVID-19 were examined and treated in accordance with the Interim guidelines “Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)” effective at the time of therapy. Additionally, on days 3–7 after hospitalization, a blood test was performed once to determine the level of metalloproteinase ADAMTS-13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13), ADAMTS-13 activity, ADAMTS-13 inhibitor and von Willebrand factor (vWF) level.Results. It was shown that the average age of the patients was 56.96 ± 7.55 years, the length of hospitalization ranged from 7 to 19 (13.0 ± 3.79) days. The disease severity was assessed by the degree of lung tissue damage based on computed tomography (CT), respiratory failure and development of systemic inflammatory response syndrome (SIRS). During hospitalization, CT-2 was detected in 46 (63.9 %) patients, CT-3 – in 26 (36.1 %) patients; 37 (51.4 %) patients were transferred to the intensive care unit (ICU). Clinically significant deep vein thrombosis (DVT) was diagnosed in 9 (12.5 %) patients, and pulmonary embolism (PE) – in 4 (5.6 %) patients. Of these, 6 cases of DVT and 3 cases of PE were fatal. A total of 14 (19.44 %) patients deceased due to developing acute cardiopulmonary failure. A vWF/ADAMTS-13 ratio greater than 2.1 was found in all ICU patients. Despite anticoagulant therapy, patients with DVT and PE had this ratio higher than 3.3 (4.00 ± 0.48), whereas in all 14 deceased patients it exceeded 2.98.Conclusion. Venous thromboembolism, including PE and DVT, has been identified as а serious complication of COVID-19. An opportunity to predict them early is of special importance because they may lead to serious complications such as disseminated intravascular coagulation, SIRS, cardiopulmonary failure, and death. In patients suffering from cancer infected with COVID-19, not only a decline in ADAMTS-13 activity and level was detected, but also a parallel increase in vWF level. A vWF/ADAMTS-13 ratio may be an early indicator of COVID-19 severity in such patients: a vWF/ADAMTS-13 ratio exceeding 2.1 was common for all ICU patients. Hence, it evidences about a potential for using this parameter to early identify such risk patients who may require more intensive care and medical intervention.
format Article
id doaj-art-4629f987409d40e4a73c66f2867d75e7
institution DOAJ
issn 2313-7347
2500-3194
language Russian
publishDate 2024-07-01
publisher IRBIS LLC
record_format Article
series Акушерство, гинекология и репродукция
spelling doaj-art-4629f987409d40e4a73c66f2867d75e72025-08-20T03:19:14ZrusIRBIS LLCАкушерство, гинекология и репродукция2313-73472500-31942024-07-0118328629910.17749/2313-7347/ob.gyn.rep.2024.519890COVID-19 impact on thrombotic complications in cancer patientsA. V. Vorobev0S. E. Einullaeva1A. S. Borodulin2M. A. Shikina3S. A. Aliev4A. G. Solopova5V. N. Galkin6A. E. Ivanov7V. O. Bitsadze8J. Kh. Khizroeva9D. V. Blinov10J.-C. Gris11I. Elalamy12A. D. Makatsariya13Sechenov UniversitySechenov UniversitySechenov UniversitySechenov UniversitySechenov UniversitySechenov UniversityYudin City Clinical Hospital, Moscow Healthcare DepartmentYudin City Clinical Hospital, Moscow Healthcare DepartmentSechenov UniversitySechenov UniversitySechenov University; Institute for Preventive and Social Medicine; Moscow Haass Medical – Social InstituteSechenov University; University of MontpellierSechenov University; Medicine Sorbonne University; Hospital TenonSechenov UniversityAim: to study the features of thrombotic complications in cancer patients during COVID-19 infection, and identify the most significant diagnostic and prognostic criteria.Materials and Methods. Within the framework of cohort non-randomized study, there were analyzed the course of coronavirus infection in 72 hospitalized patients with uterine cancer (n = 22), cervical cancer (n = 19), ovarian cancer (n = 24) as well as vaginal and vulvar cancer (n = 7). All patients hospitalized for COVID-19 were examined and treated in accordance with the Interim guidelines “Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)” effective at the time of therapy. Additionally, on days 3–7 after hospitalization, a blood test was performed once to determine the level of metalloproteinase ADAMTS-13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13), ADAMTS-13 activity, ADAMTS-13 inhibitor and von Willebrand factor (vWF) level.Results. It was shown that the average age of the patients was 56.96 ± 7.55 years, the length of hospitalization ranged from 7 to 19 (13.0 ± 3.79) days. The disease severity was assessed by the degree of lung tissue damage based on computed tomography (CT), respiratory failure and development of systemic inflammatory response syndrome (SIRS). During hospitalization, CT-2 was detected in 46 (63.9 %) patients, CT-3 – in 26 (36.1 %) patients; 37 (51.4 %) patients were transferred to the intensive care unit (ICU). Clinically significant deep vein thrombosis (DVT) was diagnosed in 9 (12.5 %) patients, and pulmonary embolism (PE) – in 4 (5.6 %) patients. Of these, 6 cases of DVT and 3 cases of PE were fatal. A total of 14 (19.44 %) patients deceased due to developing acute cardiopulmonary failure. A vWF/ADAMTS-13 ratio greater than 2.1 was found in all ICU patients. Despite anticoagulant therapy, patients with DVT and PE had this ratio higher than 3.3 (4.00 ± 0.48), whereas in all 14 deceased patients it exceeded 2.98.Conclusion. Venous thromboembolism, including PE and DVT, has been identified as а serious complication of COVID-19. An opportunity to predict them early is of special importance because they may lead to serious complications such as disseminated intravascular coagulation, SIRS, cardiopulmonary failure, and death. In patients suffering from cancer infected with COVID-19, not only a decline in ADAMTS-13 activity and level was detected, but also a parallel increase in vWF level. A vWF/ADAMTS-13 ratio may be an early indicator of COVID-19 severity in such patients: a vWF/ADAMTS-13 ratio exceeding 2.1 was common for all ICU patients. Hence, it evidences about a potential for using this parameter to early identify such risk patients who may require more intensive care and medical intervention.https://www.gynecology.su/jour/article/view/2088covid-19thrombotic complicationsoncological diseasesvwf/adamts-13 axispulmonary embolismpedeep vein thrombosisdvtsystemic inflammatory response syndromesirs
spellingShingle A. V. Vorobev
S. E. Einullaeva
A. S. Borodulin
M. A. Shikina
S. A. Aliev
A. G. Solopova
V. N. Galkin
A. E. Ivanov
V. O. Bitsadze
J. Kh. Khizroeva
D. V. Blinov
J.-C. Gris
I. Elalamy
A. D. Makatsariya
COVID-19 impact on thrombotic complications in cancer patients
Акушерство, гинекология и репродукция
covid-19
thrombotic complications
oncological diseases
vwf/adamts-13 axis
pulmonary embolism
pe
deep vein thrombosis
dvt
systemic inflammatory response syndrome
sirs
title COVID-19 impact on thrombotic complications in cancer patients
title_full COVID-19 impact on thrombotic complications in cancer patients
title_fullStr COVID-19 impact on thrombotic complications in cancer patients
title_full_unstemmed COVID-19 impact on thrombotic complications in cancer patients
title_short COVID-19 impact on thrombotic complications in cancer patients
title_sort covid 19 impact on thrombotic complications in cancer patients
topic covid-19
thrombotic complications
oncological diseases
vwf/adamts-13 axis
pulmonary embolism
pe
deep vein thrombosis
dvt
systemic inflammatory response syndrome
sirs
url https://www.gynecology.su/jour/article/view/2088
work_keys_str_mv AT avvorobev covid19impactonthromboticcomplicationsincancerpatients
AT seeinullaeva covid19impactonthromboticcomplicationsincancerpatients
AT asborodulin covid19impactonthromboticcomplicationsincancerpatients
AT mashikina covid19impactonthromboticcomplicationsincancerpatients
AT saaliev covid19impactonthromboticcomplicationsincancerpatients
AT agsolopova covid19impactonthromboticcomplicationsincancerpatients
AT vngalkin covid19impactonthromboticcomplicationsincancerpatients
AT aeivanov covid19impactonthromboticcomplicationsincancerpatients
AT vobitsadze covid19impactonthromboticcomplicationsincancerpatients
AT jkhkhizroeva covid19impactonthromboticcomplicationsincancerpatients
AT dvblinov covid19impactonthromboticcomplicationsincancerpatients
AT jcgris covid19impactonthromboticcomplicationsincancerpatients
AT ielalamy covid19impactonthromboticcomplicationsincancerpatients
AT admakatsariya covid19impactonthromboticcomplicationsincancerpatients